Passage Bio to Present at Goldman Sachs 41st Annual Global Healthcare Conference
June 04 2020 - 8:00AM
Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company
focused on developing transformative therapies for rare, monogenic
central nervous system disorders, today announced that management
will participate in a fireside chat at the virtual Goldman Sachs
41st Annual Global Healthcare Conference on Thursday, June 11, 2020
at 11:20am ET.
A live audio webcast of the fireside chat will be available on
the Investors & Media section of Passage Bio’s website at
investors.passagebio.com. A replay of the webcast will be available
for 30 days following the presentation.
About Passage Bio Passage Bio is a genetic
medicines company focused on developing transformative therapies
for rare, monogenic central nervous system disorders with limited
or no approved treatment options. The company is based in
Philadelphia, PA and has a research, collaboration and license
agreement with the University of Pennsylvania and its Gene Therapy
Program (GTP). The GTP conducts discovery and IND-enabling
preclinical work and Passage Bio conducts all clinical development,
regulatory strategy and commercialization activities under the
agreement. The company has a development portfolio of six product
candidates, with the option to license eleven more, with lead
programs in GM1 gangliosidosis, frontotemporal dementia and Krabbe
disease.
For further information, please contact:
Investors:Sarah McCabeStern Investor Relations,
Inc.212-362-1200sarah.mccabe@sternir.com
Media:Azeem
ZeekryaHDMZ312-506-5244azeem.zeekrya@hdmz.com
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Jul 2024 to Aug 2024
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Aug 2023 to Aug 2024